On April 12th, Hilary Bricken moderated our firm’s webinar titled “Current Ketamine Regulations & The Future of Psychedelic Medicines.” In that webinar, Hilary, Griffen Thorne, and I (Ethan Minkin) discussed the new proposed telehealth regulations from the DEA regarding the Ryan Haight Act of 2008 that will undoubtedly affect the ketamine telehealth industry. We also discussed the FDA approval status of other psychedelic medicines. If you missed this webinar, the replay is just below. I’ll also cover some of the highlights further down, in this blog post.
Webinar Recap: Ketamine Regulations & The Future of Therapeutic Psychedelic Medicines